← Back to Search

Tyrosine Kinase Inhibitor

DS-3201b for Small Cell Lung Cancer

Phase 1 & 2
Waitlist Available
Led By Charles Rudin, MD, PhD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug, DS-3201b, combined with irinotecan, for people whose small cell lung cancer has returned. The goal is to see if this combination is safe and more effective in treating the cancer. Irinotecan has shown significant activity against small cell lung cancer and has been combined with various other drugs in previous studies.

Eligible Conditions
  • Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Maximum Tolerated Dose (MTD) (Phase l) of DS-3201/Valemetostat
Objective Response Rate (ORR) (Phase II)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: DS-3201b and IrinotecanExperimental Treatment2 Interventions
The first part of this study is a phase I trial to assess the safety and tolerability of DS-3201b in combination with fixed-dose irinotecan. The second part of this study will be an open label, single-arm phase II study of DS-3201b at the established recommended phase II dose (RP2D) in combination with fixed-dose irinotecan.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
irinotecan
2002
Completed Phase 3
~3930
DS-3201b
2019
Completed Phase 1
~30

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,969 Previous Clinical Trials
597,229 Total Patients Enrolled
Charles Rudin, MD, PhDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
W. Victoria Lai, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
~3 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top